Report
Karen Andersen
EUR 100.00 For Business Accounts Only

Swedish Orphan Biovitrum FVE Intact Following 3Q Results as Roche's Hemlibra Poised to Compete

We're not making any significant changes to our fair value estimate for Swedish Orphan Biovitrum following third-quarter results and the incorporation of future emapalumab cash flows into our discounted cash flow model. We continue to assume a 50% probability that the firm is acquired at a similar sales multiple as Bioverativ and a 50% probability using our stand-alone fair value estimate. We do not assign Swedish Orphan Biovitrum an economic moat, given the firm's reliance on profits from two h...
Underlying
Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB is a healthcare company focused on rare diseases. Co. develops, manufactures and commercializes treatments with a particular focus on four therapeutic areas: Inflammation, Genetics & Metabolism, Haemophilia and Neonatology. Co. also markets a portfolio of rare disease products for partner companies. Co.'s pipeline programmes include research and development focused on recombinant protein drugs in late preclinical and clinical phase for indications.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Karen Andersen

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch